Mary Kay Fenton's most recent trade in Cullinan Oncology Inc was a trade of 120,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Oncology Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 60,000 | 60,000 | - | 0 | Common Stock | |
| Cullinan Oncology Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Mary Kay Fenton | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 03 Jul 2023 | 12,946 | 68,054 | - | 3.1 | 39,874 | Common Stock |
| Talaris Therapeutics Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 150,000 | 150,000 | - | - | Stock Appreciation Right | |
| Talaris Therapeutics Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2022 | 80,000 | 81,000 | - | 0 | Common Stock | |
| Talaris Therapeutics Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Mary Kay Fenton | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 13.00 per share. | 01 Feb 2022 | 1,000 | 1,000 | - | 13 | 13,000 | Common Stock |